{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:07:06Z","timestamp":1790719626237,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007472","name":"University of Kentucky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007472","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajgponline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Geriatric Psychiatry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jagp.2025.08.010","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T12:31:36Z","timestamp":1771590696000},"page":"591-601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["A Comparative Analysis of Fatal Outcomes in 5,370 Geriatric Versus 12,254 Nongeriatric Adult Patients: A Clozapine Study in VigiBase"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7756-2314","authenticated-orcid":false,"given":"Jose","family":"de Leon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1625-7367","authenticated-orcid":false,"given":"Can-Jun","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3851-4117","authenticated-orcid":false,"given":"Georgios","family":"Schoretsanitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2948-3782","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Verdoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2534-4160","authenticated-orcid":false,"given":"Joseph","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6788-4435","authenticated-orcid":false,"given":"Emilio J.","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5742-905X","authenticated-orcid":false,"given":"Carlos","family":"De las Cuevas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jagp.2025.08.010_bib0001","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000507638","article-title":"A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology","volume":"89","author":"de Leon","year":"2020","journal-title":"Psychother Psychosom"},{"issue":"9","key":"10.1016\/j.jagp.2025.08.010_bib0002","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1998","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"10.1016\/j.jagp.2025.08.010_bib0003","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","article-title":"Clozapine treatment for suicidality in schizophrenia: international Suicide Prevention Trial (InterSePT)","volume":"60","author":"Meltzer","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jagp.2025.08.010_bib0004","first-page":"1","article-title":"Clozapine may consistently protect from suicidal behaviors while other antipsychotics may lack a specific protective effect: a comprehensive VigiBase study interpreted in the context of the prior literature","author":"De las Cuevas","year":"2024","journal-title":"Exp Opin Drug Saf"},{"issue":"3","key":"10.1016\/j.jagp.2025.08.010_bib0005","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/JCP.0000000000001990","article-title":"Letter to the FDA proposing major changes in the US clozapine package insert supported by clozapine experts worldwide. Part II: a review of fatal outcomes in US pharmacovigilance data and proposed changes","volume":"45","author":"de Leon","year":"2025","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.jagp.2025.08.010_bib0006","doi-asserted-by":"crossref","first-page":"183","DOI":"10.30773\/pi.2022.0293","article-title":"Reflections on the lack of consideration of ethnic ancestry to stratify clozapine dosing","volume":"20","author":"de Leon","year":"2023","journal-title":"Psychiatry Investig"},{"key":"10.1016\/j.jagp.2025.08.010_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2025.104622","article-title":"The clozapine package inserts need to reflect lower doses for Asians","volume":"110","author":"de Leon","year":"2025","journal-title":"Asian J Psychiatr"},{"issue":"3","key":"10.1016\/j.jagp.2025.08.010_bib0008","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/JCP.0000000000001987","article-title":"Letter to the FDA proposing major changes in the US clozapine package insert supported by clozapine experts worldwide. Part I: a review of the pharmacokinetic literature and proposed changes","volume":"45","author":"de Leon","year":"2025","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jagp.2025.08.010_bib0009","first-page":"165","article-title":"Adverse drug reactions and their fatal outcomes in clozapine-treated patients in VigiBase: comparing the top four reporting countries (US, UK, Canada and Australia)","volume":"268","author":"De las Cuevas","year":"2024","journal-title":"Schizophr Res"},{"issue":"1","key":"10.1016\/j.jagp.2025.08.010_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/schbul\/sbz093","article-title":"Data from the World Health Organization's pharmacovigilance database supports the prominent role of pneumonia in mortality associated with clozapine adverse drug reactions","volume":"46","author":"De Leon","year":"2020","journal-title":"Schizophr Bull"},{"issue":"4","key":"10.1016\/j.jagp.2025.08.010_bib0011","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000506355","article-title":"Around 3% of 1,300 levels were elevated during infections in a retrospective review of 131 Beijing Hospital in-patients with more than 24,000 days of clozapine treatment","volume":"89","author":"Ruan","year":"2020","journal-title":"Psychother Psychosom"},{"issue":"3","key":"10.1016\/j.jagp.2025.08.010_bib0012","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/17512433.2019.1577134","article-title":"A comprehensive review of swallowing difficulties and dysphagia associated with antipsychotics in adults","volume":"12","author":"Cicala","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.jagp.2025.08.010_bib0013","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/17425255.2023.2192401","article-title":"Respiratory aspiration during treatment with clozapine and other antipsychotics: a literature search and a pharmacovigilance study in Vigibase","volume":"19","author":"De Las Cuevas","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"8","key":"10.1016\/j.jagp.2025.08.010_bib0014","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1080\/17425255.2024.2373111","article-title":"Investigating in VigiBase over 6000 cases of pneumonia in clozapine-treated patients in the context of the literature: focus on high lethality and the association with aspiration pneumonia","volume":"20","author":"de Leon","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"10","key":"10.1016\/j.jagp.2025.08.010_bib0015","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1176\/appi.ajp.20230744","article-title":"High burden of ileus and pneumonia in clozapine-treated individuals with schizophrenia: a Finnish 25-year follow-up register study","volume":"181","author":"Partanen","year":"2024","journal-title":"Am J Psychiatry"},{"issue":"6","key":"10.1016\/j.jagp.2025.08.010_bib0016","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/17512433.2025.2520926","article-title":"Clozapine for older adults with severe mental illness: a systematic review and expert recommendations for clinical practice","volume":"18","author":"Verdoux","year":"2025","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jagp.2025.08.010_bib0017","first-page":"282","article-title":"Brief commentary: under-recognition of underuse of clozapine in treating psychotic symptoms in Parkinson's disease","volume":"268","author":"Friedman","year":"2024","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jagp.2025.08.010_bib0018","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.schres.2023.07.004","article-title":"Can clozapine be used for treatment-refractory behavioral and psychological symptoms in dementia patients?","volume":"268","author":"Schulte","year":"2024","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jagp.2025.08.010_bib0019","article-title":"Therapeutic reference range for clozapine plasma levels in Parkinson's disease or dementia: a systematic review and individual participant data meta-analysis","author":"Kuzo","year":"2025","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jagp.2025.08.010_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jagp.2025.02.016","article-title":"Effectiveness of clozapine compared to non-clozapine antipsychotics in older adults with schizophrenia in Brazil in a 16-year follow-up","author":"Vieira","year":"2025","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.jagp.2025.08.010_bib0021","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/17512433.2019.1617695","article-title":"A comprehensive review of the clinical utility of and a combined analysis of the clozapine\/norclozapine ratio in therapeutic drug monitoring for adult patients","volume":"12","author":"Schoretsanitis","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jagp.2025.08.010_bib0022","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/JCP.0000000000001050","article-title":"Gemfibrozil may decrease norclozapine elimination: a case report","volume":"39","author":"Barclay","year":"2019","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jagp.2025.08.010_bib0023","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.schres.2023.11.010","article-title":"Revealing the reporting disparity: vigiBase highlights underreporting of clozapine in other Western European countries compared to the UK","volume":"268","author":"De Las Cuevas","year":"2024","journal-title":"Schizophr Res"},{"issue":"9","key":"10.1016\/j.jagp.2025.08.010_bib0024","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1080\/17425255.2022.2122813","article-title":"Respiratory aspiration during treatment with benzodiazepines, antiepileptic and antidepressant drugs in the pharmacovigilance database from VigiBase","volume":"18","author":"De Las Cuevas","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"10.1016\/j.jagp.2025.08.010_bib0025","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1192\/bjp.2024.140","article-title":"Clozapine, relapse, and adverse events: a 10-year electronic cohort study in Canada","volume":"225","author":"Balbuena","year":"2024","journal-title":"Br J Psychiatry"},{"issue":"3","key":"10.1016\/j.jagp.2025.08.010_bib0026","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00455-016-9695-9","article-title":"A systematic review of the prevalence of oropharyngeal dysphagia in stroke, Parkinson's disease, Alzheimer's disease, head injury, and pneumonia","volume":"31","author":"Takizawa","year":"2016","journal-title":"Dysphagia"},{"issue":"6","key":"10.1016\/j.jagp.2025.08.010_bib0027","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/00001648-199710000-00010","article-title":"Mortality in current and former users of clozapine","volume":"8","author":"Walker","year":"1997","journal-title":"Epidemiology"},{"key":"10.1016\/j.jagp.2025.08.010_bib0028","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.schres.2023.09.029","article-title":"Association between initial clozapine titration and pneumonia risk among patients with schizophrenia in a Korean tertiary hospital","volume":"268","author":"Kang","year":"2024","journal-title":"Schizophr Res"},{"issue":"2","key":"10.1016\/j.jagp.2025.08.010_bib0029","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/a-1625-6388","article-title":"An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels","volume":"55","author":"de Leon","year":"2022","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"10.1016\/j.jagp.2025.08.010_bib0030","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.rpsm.2022.06.001","article-title":"A Covid-19 outbreak in a Spanish long-term psychiatric hospital led to infections in 6 clozapine patients: elevations in their plasma clozapine levels","volume":"15","author":"Arrojo-Romero","year":"2022","journal-title":"Rev Psiquiatr Salud Ment (Engl Ed)"},{"issue":"6","key":"10.1016\/j.jagp.2025.08.010_bib0031","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S2215-0366(24)00097-X","article-title":"Long-term persistence of the risk of agranulocytosis with clozapine compared with other antipsychotics: a nationwide cohort and case-control study in Finland","volume":"11","author":"Rubio","year":"2024","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"10.1016\/j.jagp.2025.08.010_bib0032","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/acps.12898","article-title":"Meta-analysis examining the epidemiology of clozapine-associated neutropenia","volume":"138","author":"Myles","year":"2018","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.jagp.2025.08.010_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14740338.2025.2518234","article-title":"Clozapine-treated patients and myocardial infarction in adults: a pharmacovigilance study in VigiBase interpreted in the context of the literature","author":"De Las Cuevas","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jagp.2025.08.010_bib0034","first-page":"293","article-title":"Exploring low clozapine C\/D ratios, inverted clozapine- norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients: a literature review and a case series of 17 patients from 3 studies","volume":"268","author":"Ruan","year":"2024","journal-title":"Schizophr Res"},{"issue":"2","key":"10.1016\/j.jagp.2025.08.010_bib0035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/acps.13208","article-title":"Adherence to clozapine vs. other antipsychotics in schizophrenia","volume":"142","author":"Takeuchi","year":"2020","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"10.1016\/j.jagp.2025.08.010_bib0036","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/wps.20699","article-title":"20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)","volume":"19","author":"Taipale","year":"2020","journal-title":"World Psychiatry"},{"issue":"4","key":"10.1016\/j.jagp.2025.08.010_bib0037","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.rpsm.2021.07.004","article-title":"Clozapine-associated myocarditis in the World Health Organization's pharmacovigilance database: focus on reports from various countries","volume":"15","author":"De Las Cuevas","year":"2022","journal-title":"Rev Psiquiatr Salud Ment (Engl Ed)"},{"key":"10.1016\/j.jagp.2025.08.010_bib0038","doi-asserted-by":"crossref","DOI":"10.1097\/JCP.0000000000002088","article-title":"Fatal outcomes in use of clozapine: a VigiBase study of 6,402 women and 11,222 men","author":"De las Cuevas","year":"2025","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.jagp.2025.08.010_bib0039","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/wps.20707","article-title":"Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-generation antipsychotics","volume":"19","author":"de Leon","year":"2020","journal-title":"World Psychiatry"}],"container-title":["The American Journal of Geriatric Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1064748125004555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1064748125004555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T01:57:24Z","timestamp":1772243844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1064748125004555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1064748125004555"],"URL":"https:\/\/doi.org\/10.1016\/j.jagp.2025.08.010","relation":{},"ISSN":["1064-7481"],"issn-type":[{"value":"1064-7481","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Comparative Analysis of Fatal Outcomes in 5,370 Geriatric Versus 12,254 Nongeriatric Adult Patients: A Clozapine Study in VigiBase","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Geriatric Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jagp.2025.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}